Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].” Eur J Cancer 103 (November 2018): 287. https://doi.org/10.1016/j.ejca.2018.09.022.

PMID
30270112
Full Text

Staehler, M., R. J. Motzer, D. J. George, H. S. Pandha, F. Donskov, B. Escudier, A. J. Pantuck, et al. “Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.” Ann Oncol 29, no. 10 (October 1, 2018): 2098–2104. https://doi.org/10.1093/annonc/mdy329.

PMID
30412222
Full Text

Gao, Xin, Opeyemi Jegede, Connor Gray, Paul J. Catalano, Jesse Novak, David J. Kwiatkowski, Rana R. McKay, et al. “Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.” Clin Genitourin Cancer 16, no. 5 (October 2018): 341–48. https://doi.org/10.1016/j.clgc.2018.04.001.

PMID
29754934
Full Text

Choueiri, T. K., A. Flaifel, W. Xie, D. Braun, M. Ficial, R. Jennings, A. Nassar, et al. “PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials.” In Ann Oncol, 29 Suppl 8:viii726, 2018. https://doi.org/10.1093/annonc/mdy424.040.

PMID
32138002
Full Text

Harrison, M. R., P. G. Davis, M. G. Khouri, R. T. Gupta, A. J. Armstrong, M. A. McNamara, T. Zhang, et al. “EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naïve prostate cancer (HSPC).” In Ann Oncol, 29 Suppl 8:viii623–24, 2018. https://doi.org/10.1093/annonc/mdy300.064.

PMID
32137677
Full Text

George, D. J., A. J. Pantuck, R. Figlin, B. Escudier, S. Halabi, M. Casey, X. Lin, L. Serfass, M. J. Lechuga Frean, and A. Ravaud. “Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.” In Ann Oncol, 29 Suppl 8:viii312, 2018. https://doi.org/10.1093/annonc/mdy283.090.

PMID
32136726
Full Text

Bakthavatsalam, Subha, Mark L. Sleeper, Azim Dharani, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.” Angew Chem Int Ed Engl 57, no. 39 (September 24, 2018): 12780–84. https://doi.org/10.1002/anie.201807582.

PMID
30025197
Full Text

Powles, Thomas, Robert J. Motzer, Bernard Escudier, Sumanta Pal, Christian Kollmannsberger, Joanna Pikiel, Howard Gurney, et al. “Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.” Br J Cancer 119, no. 6 (September 2018): 663–69. https://doi.org/10.1038/s41416-018-0164-0.

PMID
30197417
Full Text

Freedman, Jennifer A., Yanru Wang, Xuechan Li, Hongliang Liu, Patricia G. Moorman, Daniel J. George, Norman H. Lee, Terry Hyslop, Qingyi Wei, and Steven R. Patierno. “Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival.” Carcinogenesis 39, no. 7 (July 3, 2018): 879–88. https://doi.org/10.1093/carcin/bgy062.

PMID
29726910
Full Text

LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer.” In Cancer Epidemiology Biomarkers & Prevention, 27:46–46. AMER ASSOC CANCER RESEARCH, 2018.

Scholars@Duke

Pages